Previous 10 | Next 10 |
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completion and settlement of its US$110 million private placement led by a strategic US investor gr...
Mesoblast Limited ([[MESO]] -2.7%) has announced that it has entered into a subscription agreement worth $110M (A$138M) with the issue of 60M shares in a private placement led by a strategic US investor group (SurgCenter Development).The per-share price of A$2.30 implies a ~6.5% dis...
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) announced today it has entered into subscription agreements for a total of US$110 million via the issue of 60 million shares in a private placement led by a strategic US investor group (SurgCenter Developm...
Pediatrics (Journal of the American Academy of Pediatrics) has published a paper on the first two children treated with Mesoblast’s (MESO) mesenchymal stromal cell ((MSC)) product candidate remestemcel-L for multisystem inflammatory syndrome (MIS-C) associated with COVID-19. The two pa...
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics (Journal of the American Academy of Pediatrics) has published a paper on the first two children...
Mesoblast Limited (MESO) has announced the Phase 3 results for its allogeneic mesenchymal precursor cell (“MPC”) therapy rexlemestrocel-L in patients with chronic low back pain (“CLBP”) due to degenerative disc disease (“DDD”).The 404 patients who wer...
On Thursday morning, biotech company Mesoblast Limited (NASDAQ: MESO) released data from a phase 3 clinical trial for one of its leading pipeline candidates, rexlemestrocel-L. Investors seem to be impressed with this data since the company's shares are rising sharply as a result. As...
AC Immune SA (ACIU) +112% as its vaccine generates potent anti-pTau antibody response in a phase 1b/2a study.RCM Technologies, Inc. (RCMT) +92%.Sundial Growers Inc. (SNDL) +48%.MicroVision, Inc. (MVIS) +44% after long range lidar update.Monopar Therapeutics (MNPR) +41% on poten...
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase 3 randomized controlled trial of its allogeneic mesenchymal precursor cell (MPC) therapy rex...
Longeveron has filed proposed terms for a $25 million IPO. The firm is developing a treatment for Alzheimer's Disease and other age-related conditions. LGVN is thinly capitalized and has scant chance of an AD treatment where major pharmas have failed, so I'll pass on the IPO. ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...